HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LONGBIO-B

114.900

-1.500-1.29%

Volume:27.65K

Turnover:3.19M

Market Cap:8.77B

PE:-31.77

High:118.100

Open:114.700

Low:111.700

Close:116.400

52wk High:165.900

52wk Low:72.650

Shares:76.32M

HK Float Shares:75.06M

Volume Ratio:0.35

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-3.617

ROE:--

ROA:-54.56%

PB:53.48

PE(LYR):-31.77

PS:- -

Loading ...

Overview Company News Filings

LongBio Pharma proposes board reshuffle and initiates H-share full circulation

Bulletin Express

LongBio Pharma Schedules 10 September 2026 EGM to Appoint Non-Executive Director

Bulletin Express

Longbio Pharma Announces Extraordinary General Meeting

LongBio Pharma Names Xue Kailu as Non-Executive Director, Replacing Chen Kan

LONGBIO-B Reports Interim Loss of RMB 135 Million, Widening by 43.1% Year-on-Year

LongBio Pharma: BLA Filed for Core Anti-IgE Drug as R&D Spend Jumps 61% and IPO Lifts Cash to RMB1.21 Billion

Bulletin Express

LongBio Pharma FY26 H1 Net Loss Widens 43.1% to RMB 134.81 Million

LongBio Pharma's Allergic Rhinitis Drug Application Accepted in China

MT Newswires Live

LongBio Pharma’s LP-003 BLA for Seasonal Allergic Rhinitis Accepted by China’s NMPA

Bulletin Express

LONGBIO-B's Key Allergy Drug Candidate LP-003 Receives Regulatory Acceptance for Seasonal Allergic Rhinitis

LongBio Pharma Says China Regulator Accepts LP-003 BLA for Seasonal Allergic Rhinitis

Longbio Pharma (Suzhou) Co - Nmpa Accepts Bla for Lp-003 for Seasonal Allergic Rhinitis

THOMSON REUTERS

LongBio Pharma Sets 21 August 2026 Board Meeting to Review 1H26 Results and Potential Dividend

Bulletin Express

LongBio Pharma Sets Board Meeting to Review Interim Results, Consider Dividend

LONGBIO-B Proposes Implementation of H Share Option and Incentive Schemes

Longbio Pharma Proposes H-share Option, Incentive Plans with 10% Scheme Cap

LONGBIO-B: FDA Clears LP-003 Clinical Trial Application for Peanut Allergy

Bulletin Express

FDA Grants Approval for LONGBIO-B's LP-003 Clinical Trial Application Targeting Peanut Allergy

Longbio Pharma Says FDA Clears Lp-003 Peanut Allergy Clinical Trial Application

Longbio Pharma (suzhou) Co - FDA Approves Clinical Trial Application for Lp-3 for Peanut Allergy

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/01779/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01779","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01779\",,,,,undefined,":{"symbol":"01779","market":"HK","secType":"STK","nameCN":"LONGBIO-B","latestPrice":114.9,"timestamp":1787299686952,"preClose":116.4,"halted":0,"volume":27650,"delay":0,"changeRate":-0.01288659793814433,"floatShares":75059200,"shares":76322100,"eps":-3.6171576442064155,"marketStatus":"Market Closed","change":-1.5,"latestTime":"08-21 16:08:06","open":114.7,"high":118.1,"low":111.7,"amount":3194179,"amplitude":0.054983,"askPrice":116.7,"askSize":50,"bidPrice":114.9,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-2.9720625426373606,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1780588800000,"exchange":"SEHK","adjPreClose":116.4,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.3453383685066301,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01779\",,,,,undefined,":{"symbol":"01779","floatShares":75059200,"roa":"-54.56%","roe":"--","lyrEps":-3.617158,"volumeRatio":0.3453383685066301,"shares":76322100,"dividePrice":0,"high":118.1,"amplitude":0.054983,"preClose":116.4,"low":111.7,"week52Low":72.65,"pbRate":"53.48","week52High":165.9,"institutionHeld":0,"latestPrice":114.9,"eps":-3.6171576442064155,"divideRate":0,"volume":27650,"delay":0,"ttmEps":-2.9720625426373606,"open":114.7,"prevYearClose":96.06,"prevWeekClose":120,"prevMonthClose":96.35,"prevQuarterClose":150.9,"fiveDayClose":120,"twentyDayClose":89.15,"sixtyDayClose":96.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01779\",params:#limit:5,,,undefined,":[{"date":"2026-08-21","symbol":"01779","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787275800000,"name":null,"time":"","dateTimestamp":1787241600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01779\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01779\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1784563200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01779\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01779","date":"2026-08-21","current":-38.660021,"percent":0.470588,"low":-57.574283,"twenty":-51.877603,"median":-40.334419,"eighty":-32.925453,"high":-30.168259,"avg":-42.045944,"sd":8.564223,"marketCap":8524792935},"quantilePoints":[{"date":"2026-06-12","current":-52.571631,"twenty":-51.987096,"median":-51.066007,"eighty":-49.243383,"marketCap":10676394285},{"date":"2026-06-18","current":-52.044895,"twenty":-52.077848,"median":-51.840962,"eighty":-50.705966,"marketCap":10594781820},{"date":"2026-06-26","current":-54.937294,"twenty":-55.921485,"median":-52.086085,"eighty":-51.049188,"marketCap":11128972500},{"date":"2026-07-03","current":-38.82993,"twenty":-55.511514,"median":-52.086085,"eighty":-50.54697,"marketCap":7871893215},{"date":"2026-07-10","current":-35.616464,"twenty":-55.275063,"median":-51.840962,"eighty":-39.024704,"marketCap":7211574180},{"date":"2026-07-17","current":-31.236455,"twenty":-55.113833,"median":-50.626468,"eighty":-33.702374,"marketCap":6347223982},{"date":"2026-07-24","current":-32.543593,"twenty":-53.991029,"median":-39.576969,"eighty":-32.682309,"marketCap":6614319322},{"date":"2026-07-31","current":-35.105215,"twenty":-52.48276,"median":-38.82993,"eighty":-32.450461,"marketCap":7148510002},{"date":"2026-08-07","current":-41.09187,"twenty":-52.1108,"median":-38.793333,"eighty":-32.612951,"marketCap":8383825950},{"date":"2026-08-14","current":-43.58221,"twenty":-52.013269,"median":-39.316865,"eighty":-32.896956,"marketCap":8903178000},{"date":"2026-08-21","current":-41.637947,"twenty":-51.877603,"median":-40.334419,"eighty":-32.925453,"marketCap":8524792935}],"updateTime":1787455967023},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01779\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1134828489","title":"LongBio Pharma proposes board reshuffle and initiates H-share full circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1134828489","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134828489?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:51","pubTimestamp":1787323887,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. has announced two key corporate moves: a planned change in its non-executive directorship and the launch of an H-share full-circulation programme. Non-executive...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134108727","title":"LongBio Pharma Schedules 10 September 2026 EGM to Appoint Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1134108727","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134108727?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:48","pubTimestamp":1787323725,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. has called an extraordinary general meeting (EGM) for 10 September 2026 at 16:00 (Beijing time) in Room 302, Building 88, No. 887 Zuchongzhi Road, Zhangjiang...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661296512","title":"Longbio Pharma Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2661296512","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661296512?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:22","pubTimestamp":1787322158,"startTime":"0","endTime":"0","summary":"Longbio Pharma announces extraordinary general meetingLongBio Pharma will hold an extraordinary general meeting in Shanghai, China on Sept. 10, 2026.Shareholders will vote on appointing Xue Kailu as a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4Rhx9Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661295018","title":"LongBio Pharma Names Xue Kailu as Non-Executive Director, Replacing Chen Kan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661295018","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661295018?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:15","pubTimestamp":1787321743,"startTime":"0","endTime":"0","summary":"LongBio Pharma names Xue Kailu as non-executive director, replacing Chen KanLongBio Pharma (Suzhou) set a non-executive director change, with Chen Kan to step down effective Aug. 31, 2026.Shareholders","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL37Rjsg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190762326","title":"LONGBIO-B Reports Interim Loss of RMB 135 Million, Widening by 43.1% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1190762326","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190762326?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:51","pubTimestamp":1787305865,"startTime":"0","endTime":"0","summary":"LONGBIO-B (01779) has released its interim results for the six months ended June 30, 2026, revealing a net loss attributable to shareholders of RMB 135 million, a 43.1% increase from the same period...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149133091","title":"LongBio Pharma: BLA Filed for Core Anti-IgE Drug as R&D Spend Jumps 61% and IPO Lifts Cash to RMB1.21 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1149133091","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149133091?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:46","pubTimestamp":1787305562,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) reported interim 2026 results showing accelerated pipeline progress and a substantially strengthened balance sheet following its Hong Kong IPO. Pipeline...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LongBio Pharma: BLA Filed for Core Anti-IgE Drug as R&D Spend Jumps 61% and IPO Lifts Cash to RMB1.21 Billion","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661269135","title":"LongBio Pharma FY26 H1 Net Loss Widens 43.1% to RMB 134.81 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661269135","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661269135?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:43","pubTimestamp":1787305432,"startTime":"0","endTime":"0","summary":"LongBio Pharma FY26 H1 net loss widens 43.1% to RMB 134.81 millionLongBio Pharma posted a net loss of RMB 134.81 million, widening 43.1% from a year earlier.R&D costs climbed 60.8% to RMB 108.23 milli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL37vlkp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661687142","title":"LongBio Pharma's Allergic Rhinitis Drug Application Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2661687142","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661687142?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:53","pubTimestamp":1787298808,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou)'s (HKG:1779) biologics license application for LP-003 was accepted by China's National Medical Products Administration.The acceptance is for the indication of seasonal allergic rhinitis, according to a Friday Hong Kong bourse filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125738268","title":"LongBio Pharma’s LP-003 BLA for Seasonal Allergic Rhinitis Accepted by China’s NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1125738268","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125738268?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:45","pubTimestamp":1787265908,"startTime":"0","endTime":"0","summary":"Hong Kong–listed biopharmaceutical firm LongBio Pharma (LONGBIO-B) announced that the National Medical Products Administration (NMPA) has formally accepted its biologics license application (BLA) for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187233290","title":"LONGBIO-B's Key Allergy Drug Candidate LP-003 Receives Regulatory Acceptance for Seasonal Allergic Rhinitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1187233290","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187233290?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:26","pubTimestamp":1787264777,"startTime":"0","endTime":"0","summary":"LONGBIO-B (01779) has announced that the Biologics License Application (BLA) for LP-003, targeting the indication of seasonal allergic rhinitis, has been formally accepted for review by China's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661230121","title":"LongBio Pharma Says China Regulator Accepts LP-003 BLA for Seasonal Allergic Rhinitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2661230121","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661230121?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:18","pubTimestamp":1787264308,"startTime":"0","endTime":"0","summary":"LongBio Pharma says China regulator accepts LP-003 BLA for seasonal allergic rhinitisLongBio Pharma’s China regulator accepted a BLA for LP-003 to treat seasonal allergic rhinitis.LP-003 is an anti-Ig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL8Qkbzf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661230114","title":"Longbio Pharma (Suzhou) Co - Nmpa Accepts Bla for Lp-003 for Seasonal Allergic Rhinitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2661230114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661230114?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:17","pubTimestamp":1787264226,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nFWN44H1HU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177059964","title":"LongBio Pharma Sets 21 August 2026 Board Meeting to Review 1H26 Results and Potential Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1177059964","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177059964?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:23","pubTimestamp":1786443829,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. has scheduled a board meeting for Friday, 21 August 2026. The agenda includes approval of the unaudited interim results for the six months ended 30 June 2026 and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658529999","title":"LongBio Pharma Sets Board Meeting to Review Interim Results, Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2658529999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658529999?lang=en_us&edition=fundamental","pubTime":"2026-08-11 17:53","pubTimestamp":1786442008,"startTime":"0","endTime":"0","summary":"LongBio Pharma sets board meeting to review interim results, consider dividendLongBio Pharma (Suzhou) schedules a board meeting for Aug. 21, 2026 to review the unaudited interim results for the six mo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8THjwX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157958258","title":"LONGBIO-B Proposes Implementation of H Share Option and Incentive Schemes","url":"https://stock-news.laohu8.com/highlight/detail?id=1157958258","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157958258?lang=en_us&edition=fundamental","pubTime":"2026-07-16 06:50","pubTimestamp":1784155827,"startTime":"0","endTime":"0","summary":"The board of LONGBIO-B (01779) has resolved to propose the adoption of an H share option scheme and an H share incentive scheme for the company.The proposed schemes aim to establish and improve the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651499707","title":"Longbio Pharma Proposes H-share Option, Incentive Plans with 10% Scheme Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2651499707","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651499707?lang=en_us&edition=fundamental","pubTime":"2026-07-16 06:08","pubTimestamp":1784153288,"startTime":"0","endTime":"0","summary":"LongBio Pharma proposes H-share option, incentive plans with 10% scheme capLongBio Pharma (Suzhou) proposed adopting an H Share Option Scheme, an H Share Incentive Scheme.Equity awards could be settle","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL8vC8WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108444695","title":"LONGBIO-B: FDA Clears LP-003 Clinical Trial Application for Peanut Allergy","url":"https://stock-news.laohu8.com/highlight/detail?id=1108444695","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108444695?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:21","pubTimestamp":1783902099,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. announced that the U.S. Food and Drug Administration has approved the company’s Investigational New Drug application for LP-003 to treat peanut allergy. Food...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138810338","title":"FDA Grants Approval for LONGBIO-B's LP-003 Clinical Trial Application Targeting Peanut Allergy","url":"https://stock-news.laohu8.com/highlight/detail?id=1138810338","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138810338?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:18","pubTimestamp":1783901912,"startTime":"0","endTime":"0","summary":"LONGBIO-B has announced that its clinical trial application for LP-003 targeting the peanut allergy indication has received approval from the U.S. Food and Drug Administration (FDA).Food allergies,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BMED","01779","BK4585","BK1161","IBBQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651116145","title":"Longbio Pharma Says FDA Clears Lp-003 Peanut Allergy Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2651116145","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651116145?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:09","pubTimestamp":1783901388,"startTime":"0","endTime":"0","summary":"LongBio Pharma says FDA clears LP-003 peanut allergy clinical trial applicationLongBio Pharma (Suzhou) won US FDA clearance for its clinical trial application for LP-003 in peanut allergy.LP-003 is an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL9VKZnV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651316148","title":"Longbio Pharma (suzhou) Co - FDA Approves Clinical Trial Application for Lp-3 for Peanut Allergy","url":"https://stock-news.laohu8.com/highlight/detail?id=2651316148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651316148?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:09","pubTimestamp":1783901375,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43C16N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":57,"code":"91000000","status":"200"}]}}